Disclosures for "Treatment Characteristics and Healthcare Resource Utilization Among Patients With Generalized Myasthenia Gravis Initiating Rozanolixizumab in the United States"
-
Dr. Kumar has received personal compensation for serving as an employee of UCB. Dr. Kumar has stock in UCB.
-
Dr. Ting has nothing to disclose.
-
Dr. Heras has received personal compensation for serving as an employee of UCB Pharma S.A.
-
Ms. Nair has received personal compensation for serving as an employee of Alira Health.
-
Dr. Harrold has received personal compensation for serving as an employee of UCB.
-
Ms. Park has nothing to disclose.